Breast Cancer Patents Research - Myriad Genetics in US | Trastuzumab in India...Rahul Dev
Breast Cancer – Patents
Executive Summary
Introduction
Breast cancer is a malignancy that effects women across the world and is most prevalent among various types of cancers. Patents are jurisdiction specific exclusive rights that are sought by innovators across various technological fields.
breast-cancer-ribbon
However, patent rights become questionable and debatable when these are sought in respect of pharmaceutical drugs, medical devices, surgical techniques, diagnostic tests, personalized medicines and research tools related to healthcare. Across Western jurisdictions, patents have been sought for artificial plant varieties (hybrid plants, genetically modified plants etc.), animal species created with human intervention (Harvard Oncomouse, Dolly the Sheep etc.), and methods of human treatment. Due to the presence of numerous patents in the field of healthcare, it imminently results in the requirement of large number of licenses to access patented technology, which subsequently leads to increased cost of treatment because of accumulation of royalties (royalty stacking) to be paid to the patent holders. Therefore, in developing countries like India, it becomes highly controversial as to whether to grant such patents to protect Intellectual Property Rights (IPR) or to focus on affordable healthcare by rejecting such patents.
Strategy, Scope and Focus
With a view to discuss implications of patents specifically related to breast cancer, we have researched and analyzed the breast cancer patent landscape in India and US, in light of latest legal developments, with special focus on Trastuzumab (a medicine which treats a form of breast cancer) and US Supreme Court judgement to overturn Myriad Genetics’ patents on the “breast cancer genes - BRCA1 and BRCA2”.
Breast Cancer and Patents
Basics of Patent Rights
As it is well known that patent protection is granted for a limited period of 20 years, wherein the patent holder holds exclusive rights for exploitation of the patented invention. Generally, patents are aimed at encouraging innovations by providing incentives to the patent holders by offering them recognition for their creativity.
Biotechnology Patents
In the field of biotechnology and healthcare, the cost of reparation is crucial, as the research in these fields is highly expensive. The financial investments can only be paid off if the companies can protect results by exclusive rights (patents) and gain the competitive advantage.
Gene Therapy Patents
Historically, there has been a close relation between gene therapy, patents and scientific advancements. Large pharmaceutical companies have invested huge amount of capital in patenting genes, either on their own or by acquiring small biotech companies. For example, Swiss pharmaceutical company Sandoz (subsidiary of Novartis) acquired Genetic Therapy Inc. of Gaithersburg, Md. In 1995, for about $295 million. At that point of time, Genetic Therapy held e
After Myriad: Where next for gene patents in the US? by Patent Attorney Dr Mi...Jeremy M. Ben-David
Following the recent Supreme Court decision regarding Myriad, Dr. Hammer has sided with those who declare that "the sky has not fallen." He analyses the decision and points to the way forward. Dr. Hammer heads the "US Direct" patent prosecution practice at JMB Davis Ben-David, a US and Israel Intellectual Property Boutique located in the Har-Hotzvim high tech park in Jerusalem, Israel.
In addition to filing and prosecuting patent and trademark applications worldwide for their Israeli clients, JMB Davis Ben-David files and prosecutes patent and trademark applications for clients the world over, both in the Israeli and US Patent and Trademark Offices.
Obtaining patentable claims after Prometheus and MyriadMaryBreenSmith
The Supreme Court cases significantly changed what is patentable subject-matter in the U.S. But how broadly has the scope of patentable subject matter been narrowed by these decisions? Presentation analyzes major claim types in diagnostics and gene-type patents and whether they remain patentable under this new case law.
Breast Cancer Patents Research - Myriad Genetics in US | Trastuzumab in India...Rahul Dev
Breast Cancer – Patents
Executive Summary
Introduction
Breast cancer is a malignancy that effects women across the world and is most prevalent among various types of cancers. Patents are jurisdiction specific exclusive rights that are sought by innovators across various technological fields.
breast-cancer-ribbon
However, patent rights become questionable and debatable when these are sought in respect of pharmaceutical drugs, medical devices, surgical techniques, diagnostic tests, personalized medicines and research tools related to healthcare. Across Western jurisdictions, patents have been sought for artificial plant varieties (hybrid plants, genetically modified plants etc.), animal species created with human intervention (Harvard Oncomouse, Dolly the Sheep etc.), and methods of human treatment. Due to the presence of numerous patents in the field of healthcare, it imminently results in the requirement of large number of licenses to access patented technology, which subsequently leads to increased cost of treatment because of accumulation of royalties (royalty stacking) to be paid to the patent holders. Therefore, in developing countries like India, it becomes highly controversial as to whether to grant such patents to protect Intellectual Property Rights (IPR) or to focus on affordable healthcare by rejecting such patents.
Strategy, Scope and Focus
With a view to discuss implications of patents specifically related to breast cancer, we have researched and analyzed the breast cancer patent landscape in India and US, in light of latest legal developments, with special focus on Trastuzumab (a medicine which treats a form of breast cancer) and US Supreme Court judgement to overturn Myriad Genetics’ patents on the “breast cancer genes - BRCA1 and BRCA2”.
Breast Cancer and Patents
Basics of Patent Rights
As it is well known that patent protection is granted for a limited period of 20 years, wherein the patent holder holds exclusive rights for exploitation of the patented invention. Generally, patents are aimed at encouraging innovations by providing incentives to the patent holders by offering them recognition for their creativity.
Biotechnology Patents
In the field of biotechnology and healthcare, the cost of reparation is crucial, as the research in these fields is highly expensive. The financial investments can only be paid off if the companies can protect results by exclusive rights (patents) and gain the competitive advantage.
Gene Therapy Patents
Historically, there has been a close relation between gene therapy, patents and scientific advancements. Large pharmaceutical companies have invested huge amount of capital in patenting genes, either on their own or by acquiring small biotech companies. For example, Swiss pharmaceutical company Sandoz (subsidiary of Novartis) acquired Genetic Therapy Inc. of Gaithersburg, Md. In 1995, for about $295 million. At that point of time, Genetic Therapy held e
After Myriad: Where next for gene patents in the US? by Patent Attorney Dr Mi...Jeremy M. Ben-David
Following the recent Supreme Court decision regarding Myriad, Dr. Hammer has sided with those who declare that "the sky has not fallen." He analyses the decision and points to the way forward. Dr. Hammer heads the "US Direct" patent prosecution practice at JMB Davis Ben-David, a US and Israel Intellectual Property Boutique located in the Har-Hotzvim high tech park in Jerusalem, Israel.
In addition to filing and prosecuting patent and trademark applications worldwide for their Israeli clients, JMB Davis Ben-David files and prosecutes patent and trademark applications for clients the world over, both in the Israeli and US Patent and Trademark Offices.
Obtaining patentable claims after Prometheus and MyriadMaryBreenSmith
The Supreme Court cases significantly changed what is patentable subject-matter in the U.S. But how broadly has the scope of patentable subject matter been narrowed by these decisions? Presentation analyzes major claim types in diagnostics and gene-type patents and whether they remain patentable under this new case law.
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...Kirby Drake
This presentation provides an overview of gene patents and discusses the case of Myriad Genetics and ethics in patenting and licensing and commercializing innovations.
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESSaravanan A
This research work critically examines the current trends and future feasibility of gene patents with the help of most celebrated Myriad Genetics Gene Patent Case.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...Gary M. Myles, Ph.D.
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.
This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...Kirby Drake
This presentation provides an overview of gene patents and discusses the case of Myriad Genetics and ethics in patenting and licensing and commercializing innovations.
THE FRONTIERS OF MONOPOLIZATION OF HUMAN GENESSaravanan A
This research work critically examines the current trends and future feasibility of gene patents with the help of most celebrated Myriad Genetics Gene Patent Case.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...Gary M. Myles, Ph.D.
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.
This presentation discusses the historical context for the recent court decisions that affect the patent eligibility of biotechnology inventions, including those directed to genes, cDNAs, proteins, antibodies, and diagnostic methods. Discussed are the early Funk Brothers and Chakrabarty decisions as well as the Lab Corp, Bilski, Prometheus, Classen, and Myriad court opinions. The impact of the court holdings on the future development of biotechnology inventions, in particular personalized medicine inventions, is analyzed as is the erosion of the requisite incentives of innovative companies to invent and commercialize in areas where patent protection is less certain.
A 2015 Congressional amendment precludes Mitochondrial Replacement Therapy (MRT), a life-saving IVF-based procedure that could prevent a plethora of mitochondrial DNA diseases in the U.S. Individuals do not, at present, have access to this technology to prevent the devastating consequences of mitochondrial DNA disease. At the same time, MRT continues to move forward in other countries, such as the UK.
Has the time come to revisit the federal prohibition of this preventive therapy and research?
Expert panelists discussed the future of MRT policy in the U.S., reviewing the latest technological developments, the regulatory barriers, and the ethical challenges affecting the clinical application of MRT.
This event was free and open to the public.
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
Let's dive deeper into the world of ODC! Ricardo Alves (OutSystems) will join us to tell all about the new Data Fabric. After that, Sezen de Bruijn (OutSystems) will get into the details on how to best design a sturdy architecture within ODC.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
"Impact of front-end architecture on development cost", Viktor TurskyiFwdays
I have heard many times that architecture is not important for the front-end. Also, many times I have seen how developers implement features on the front-end just following the standard rules for a framework and think that this is enough to successfully launch the project, and then the project fails. How to prevent this and what approach to choose? I have launched dozens of complex projects and during the talk we will analyze which approaches have worked for me and which have not.
Accelerate your Kubernetes clusters with Varnish CachingThijs Feryn
A presentation about the usage and availability of Varnish on Kubernetes. This talk explores the capabilities of Varnish caching and shows how to use the Varnish Helm chart to deploy it to Kubernetes.
This presentation was delivered at K8SUG Singapore. See https://feryn.eu/presentations/accelerate-your-kubernetes-clusters-with-varnish-caching-k8sug-singapore-28-2024 for more details.
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered Quality
Ownership Rights:: Patents for Derivatives of the Human Body
1. Issues for Today and Tomorrow Ownership Rights: Patents for Derivatives of the Human Body Larnita Pette May 19, 2009 (Updated December 2011)
2.
3.
4.
5.
6.
7.
8.
Editor's Notes
Australia Whose DNA .pdf, Tonga & Iceland, Biotech, Ownership and Consent Indigenous peoples and culturally appropriate informed consent and ownership of DNA. Genomic studies are also being undertaken with populations which do not identify themselves as indigenous peoples, such as the UK, Norfolk Island, Mormons and in Iceland. Such populations are sometimes targeted because they have well documented genealogical histories, making them valuable for tracing inherited diseases. In Iceland availability of genealogies date back centuries. Informed consent claimed through an act of parliament. decode a commercial firm. October 1999, Autogen Ltd announced an agreement in principle to form a strategic alliance with Merck Lipha, a subsidiary of Merck Kga A of Darmstadt, Germany the manufacturer of metformin the world’s top selling drug for the treatment of diabetes. Metformin holds 50% of the market for the treatment of Type 2 Diabetes in Australia.- introduced to the US market in 1996, where it became the #1 best seller. Object of Autogen/Merck Human Genetics Project is discovery of human genes involved in weight imbalance, Type 2 Diabetes and insulin resistance. Details of deal to share compensation with the Tongan people and the catch which caused Autogen to abandon research on TANIS gene
Who Owns Your Body The California Supreme Court agreed that Moore did have a claim for breach of fiduciary duty and lack of informed consent because Dr. Golde had failed to disclose the extent of his research and his economic interest in Moore’s cells. The court stated in its decision, that an adult of sound mind has the right to exercise control over his own body and, within that right, should have the power of deciding whether or not to submit to lawful medical treatment. For that power to be effective, the court stated, a patient’s consent must be informed consent. The Florida district court did find that Matalon and his group had unjustly benefited from the licensing fees negotiated under the commercial patent. However, the Florida court also ruled that the case involved no patient-physician relationship—because Dr. Matalon was not a treating physician to the Canavan patients or their families—and thus found no breach of duty of informed consent. The case of Washington University v. Catalona highlights the reality, that researchers themselves have limited rights over their own work, and provides a focal point by which to explore the question: How does informed consent grant a researcher the right to explore one’s biological materials in the name of science, and does it strip consenting patients of all interests in something that is uniquely their own? The district court found that WU had alone assumed the burden of all legal, regulatory, and compliance risks with respect to all research done in connection with the biorepository that Dr. Catalona had helped to create. The court found thus that WU had, at all times, exercised undisputed and exclusive possession over the samples in question, demonstrating prima facie evidence of ownership. The court ruled that the samples were donated to WU as gifts and donors had no ownership interest in those samples. Dr. Catalona appealed the decision.